L0T.F GE HEALTHCARE TECH.INC.
- Market cap
- EUR 33.6B
- P/E
- 18.3x
- P/B
- 3.21x
- ROE
- 17.9%
- Dividend yield
- 0.19%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is L0T.F undervalued?
Graham numberL0T.F trades 61.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GE HEALTHCARE TECH.INC. fundamental analysis
No fundamental analysis for GE HEALTHCARE TECH.INC. yet.
GE HEALTHCARE TECH.INC. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GE HEALTHCARE TECH.INC.
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomog…
Full company profileGE HEALTHCARE TECH.INC. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GE HEALTHCARE TECH.INC. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 18.3B | 19.6B | 19.7B | 20.6B | 21.3B |
| Gross Profit | 7.18B | 7.92B | 8.21B | 8.25B | 8.51B |
| Operating Income | 2.52B | 2.44B | 2.63B | 2.76B | 2.74B |
| EBITDA | 3.23B | 3.51B | 3.67B | 3.79B | 3.68B |
| Net Income | 1.92B | 1.57B | 1.99B | 2.08B | 2.08B |
| EPS | 4.22 | 3.44 | 4.36 | 4.57 | 4.61 |
| Balance Sheet | |||||
| Total Assets | 27.5B | 32.5B | 33.1B | 36.9B | 38.4B |
| Total Liabilities | 17.9B | 25.1B | 24.4B | 26.3B | 26.5B |
| Shareholders' Equity | 9.36B | 7.13B | 8.45B | 10.4B | 11.6B |
| Cash & Short-term Investments | 1.44B | 2.49B | 2.87B | 4.49B | 2.83B |
| Cash Flow | |||||
| Operating Cash Flow | 2.11B | 2.10B | 1.95B | 1.99B | 1.82B |
| Capital Expenditure | 310M | 387M | 401M | 482M | 523M |
| Free Cash Flow | 1.80B | 1.71B | 1.55B | 1.51B | 1.30B |
| Ratios | |||||
| ROE | 20.5% | 22.0% | 23.6% | 20.1% | 17.9% |
| ROA | 7.0% | 4.8% | 6.0% | 5.6% | 5.4% |
| Net Profit Margin | 10.4% | 8.0% | 10.1% | 10.1% | 9.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
GE HEALTHCARE TECH.INC. dividends
- Dividend yield
- 0.19%
- Forward dividend
- 0.14 EUR
- Payout ratio
- 3.1%
- Ex-dividend date
- Oct 23, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 64.0M | 0.14 | 3.1% |
| 2024 | USD 55.0M | 0.12 | 2.8% |
| 2023 | USD 41.0M | 0.09 | 2.6% |
| 2022 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns GE HEALTHCARE TECH.INC.
- Insiders 0.37%
- Institutions 96.13%
- Public & others 3.50%
- Shares outstanding 452M
- Free float 451M
GE HEALTHCARE TECH.INC. company profile
- Company name
- GE HEALTHCARE TECH.INC.
- Ticker
- L0T.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 54,000
- Fiscal year end
- December
- Address
- 500 West Monroe Street, Chicago, IL, United States, 60661
- Phone
- 833 735 1139
- Website
- gehealthcare.com
About GE HEALTHCARE TECH.INC.
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
GE HEALTHCARE TECH.INC. management
10- Mr. Peter J. ArduiniPresident, CEO & Director · born 1965
- Dr. Taha Kass-Hout M.D., M.S.Chief Science & Technology Officer · born 1972
- Mr. Frank R. Jimenez Esq.General Counsel & Corporate Secretary · born 1965
- Ms. Jeannette BankesPresident & CEO of Patient Care Solutions · born 1971
- Mr. William K. GroganChief Financial Officer · born 1979
- Mr. George Andrew NewcombController & Chief Accounting Officer · born 1967
- Mr. Jahidul H. KhandakerChief Information Officer · born 1971
- Ms. Carolynne BordersChief Investor Relations Officer
- Ms. Rana StrellisChief Corporate Marketing & Communications Officer
- Mr. Adam Y. HoltonChief People Officer · born 1971